Premium
Exploratory analysis of prognostic factors for lenvatinib in radioiodine‐refractory differentiated thyroid cancer
Author(s) -
Suzuki Chiaki,
Kiyota Naomi,
Imamura Yoshinori,
Goto Hideaki,
Suto Hirotaka,
Chayahara Naoko,
Toyoda Masanori,
Ito Yasuhiro,
Miya Akihiro,
Miyauchi Akira,
Otsuki Naoki,
Nibu Kenichi,
Minami Hironobu
Publication year - 2019
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.25784
Subject(s) - lenvatinib , medicine , refractory (planetary science) , oncology , thyroid cancer , multivariate analysis , cancer , physics , astrobiology
Background Multitarget kinase inhibitors (m‐TKI), including lenvatinib, are now available as treatment options for radioiodine‐refractory differentiated thyroid cancer (RR‐DTC). However, the optimal timing of treatment initiation with m‐TKI in these patients remains to be defined. Methods We retrospectively reviewed the clinical records of 30 consecutive patients with RR‐DTC. The relationship between clinical characteristics was evaluated, including tumor growth parameters at pretreatment/post‐treatment and efficacy of lenvatinib. Results A total of 26 patients with RR‐DTC treated with lenvatinib were evaluable for response and eligible for analysis. From the results of multivariate analysis, baseline tumor size and tumor‐related symptoms were independent negative prognostic factors for overall survival (OS) and progression‐free survival (PFS). Pretreatment tumor growth parameters were not prognostic for either PFS or OS. Conclusions Patients with RR‐DTC with a high tumor burden and tumor‐related symptoms had significantly worse prognosis. Greater tumor reduction after starting lenvatinib may lead to better prognosis, irrespective of pretreatment high tumor growth rate.